HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Exclusion Criteria

• •Distant metastasis;
• •Refused to receive PD-1 inhibitor and apatinib treatment;
• •Any of the following conditions within the first 12 months of the study: myocardial infarction, severe/unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), Pulmonary embolism; ongoing: arrhythmia grade ≥2 according to NCI-CTCAE criteria, QTc prolongation (\>450 ms in men, \>470 ms in women);
• •Renal insufficiency requires peritoneal dialysis or hemodialysis;
• •Serious dysfunction of other important organs;
• •A second primary malignant tumor was diagnosed in the past;
• •Known or new evidence of brain or leptomeningeal lesions;
• •Hemophilia or bleeding tendency, who are taking anticoagulation therapy such as coumarin derivatives in therapeutic doses;
• •Pregnant or lactating women, all female patients of childbearing potential must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative;
• •History of previous organ transplantation;
• •Known HIV infection;
• •Allergy to chemotherapy drugs;
• •Patients with other serious acute or chronic physical or psychiatric diseases or abnormal laboratory tests that may increase the risk associated with participating in the study, or may interfere with the interpretation of the study results or the investigators consider unsuitable for enrollment.